<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="156478">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01062685</url>
  </required_header>
  <id_info>
    <org_study_id>2008-000323</org_study_id>
    <nct_id>NCT01062685</nct_id>
  </id_info>
  <brief_title>Near Infrared Spectroscopy</brief_title>
  <acronym>St02</acronym>
  <official_title>Near Infrared Spectroscopy (NIRS) to Measure Tissue Oxygen Saturation (St02)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hutchinson Technologies</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Beth Israel Deaconess Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall hypotheses of this project is that Near Infrared Spectroscopy (NIRS) can be used
      to identify morbidity, mortality, and resource utilization in patients with sepsis and
      septic shock.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Near Infrared Spectroscopy (NIRS) can be utilized to measure tissue oxygenation, offering
      promise as a guide in the early treatment of severe sepsis; however, the role and utility of
      this technology is still evolving. Three distinct ways to measure StO2 have been proposed:
      1) initial random spot-check measurements (StO2 initial); 2) minimum value over a 3-hour
      observation period (StO2 min); and, 3) changes in StO2 in response to an ischemic challenge
      (change in StO2 and StO2 slope). The purpose of this study is to assess the diagnostic
      ability of each of these parameters to predict morbidity, mortality, and resource
      utilization.

      This study will utilize the Hutchinson InSpectra StO2 tissue oxygenation monitor, which is
      FDA approved for use in monitoring patients during circulatory or perfusion examinations of
      skeletal muscle, or when there is a suspicion of compromised circulation.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Anticipated">September 2016</completion_date>
  <primary_completion_date type="Anticipated">September 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Organ Dysfunction and Severity of Illness</measure>
    <time_frame>time 0 - 24 hrs</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>In hospital</time_frame>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Septic Shock</condition>
  <arm_group>
    <arm_group_label>Septic Shock Cohort</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Sepsis cohort</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Pre-shock cohort</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-Infected controls</arm_group_label>
    <description>Non-infected controls that are age and sex matched on a 1:1 basis with the septic shock cohort.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood, serum
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Emergency Department
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        There will be three cohorts enrolled in this study-

        A. Septic Shock Cohort (n=60)

        Inclusion criteria:

          1. Suspected infection

          2. Any two of four criteria of systemic inflammatory response:

               1. Temperature &gt; 100.4° or &lt; 96.8° F

               2. Heart rate &gt; 90 beats/minute

               3. Respiratory rate &gt; 20 breaths/min. or PaCO2 &lt; 32 mm Hg

               4. WBC &gt;12,000 or &lt; 4000 cells/µL or &gt; 10% bands

          3. Evidence of hypoperfusion evidenced by either of the following:

               1. SBP &lt; 90 mm Hg after 20cc/kg crystalloid

               2. a whole blood lactate &gt; 4 mmol/L

               3. vasopressor use

        Exclusion criteria:

          1. Age &lt; 18 years

          2. Pregnancy

          3. Acute traumatic or burn injury (primary diagnosis)

          4. Acute cerebrovascular event (primary diagnosis)

          5. Acute coronary syndrome (primary diagnosis)

          6. Acute pulmonary edema (primary diagnosis)

          7. Cardiac dysrhythmia (primary diagnosis)

          8. Acute and active gastrointestinal bleeding (primary diagnosis)

          9. Acute drug overdose (primary diagnosis)

         10. Requirement for immediate surgery

        B. Sepsis Cohort (n=60)

        Inclusion Criteria:

          1. Suspected infection

          2. Any two of four criteria of systemic inflammatory response:

               1. Temperature &gt; 100.4° or &lt; 96.8° F

               2. Heart rate &gt; 90 beats/minute

               3. Respiratory rate &gt; 20 breaths/min. or PaCO2 &lt; 32 mm Hg

               4. WBC &gt;12,000 or &lt; 4000 cells/µL or &gt; 10% bands

          3. NO Evidence of hypoperfusion evidenced by either of the following:

               1. SBP &lt; 90 mm Hg after 20cc/kg crystalloid

               2. a whole blood lactate &gt; 4 mmol/L

        Exclusion Criteria: per above for septic shock cohort

        C. Pre-Shock Cohort (n=60)

        Inclusion Criteria:

          1. Suspected or confirmed infection as primary reason for admission

          2. Serum Lactate ≥2.0 and &lt;4.0 mmol/L OR any SBP &lt; 90 mmHg and now &gt; 100mmHg

          3. Hospital admission planned

          4. Identification within 3 hours of lactate measurement or hypotension

        Exclusion Criteria:

          1. Age &lt; 18 years

          2. Pregnancy

          3. Evidence of Overt Shock/Hypoperfusion upon enrollment:

               -  Serum lactate ≥ 4.0 mmol/L

               -  Any vasopressor or inotrope use

          4. Mechanical ventilation before enrollment

          5. Acute traumatic or burn injury

          6. Acute cerebrovascular event

          7. Acute coronary syndrome

          8. Acute pulmonary edema

          9. Acute and active gastrointestinal bleeding

         10. Requirement for immediate surgery

         11. Inability to obtain written informed consent

         12. Known reported stable systolic blood pressure &lt; 100 mmHg

         13. Patient not eligible for vasopressor therapy (e.g. advanced directives)

        D. Non-infected Controls (n=40)

        Inclusion Criteria:

          1. No Suspected infection

          2. Absence of any systemic inflammatory response criteria:

               1. Temperature &gt; 100.4° or &lt; 96.8° F

               2. Heart rate &gt; 90 beats/minute

               3. Respiratory rate &gt; 20 breaths/min. or PaCO2 &lt; 32 mm Hg

               4. WBC &gt;12,000 or &lt; 4000 cells/µL or &gt; 10% bands

          3. NO Evidence of hypoperfusion evidenced by absence of either of the following:

               1. SBP &lt; 90 mm Hg after 20cc/kg crystalloid

               2. a whole blood lactate &gt; 4 mmol/L

        Non-infected controls will be age and sex matched on a 1:1 basis with the septic shock
        cohort.

        Exclusion Criteria: per above criteria for septic shock cohort
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nathan I Shapiro, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beth Israel Deaconess Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <lastchanged_date>September 8, 2015</lastchanged_date>
  <firstreceived_date>February 3, 2010</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beth Israel Deaconess Medical Center</investigator_affiliation>
    <investigator_full_name>Nathan Shapiro</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>septic shock</keyword>
  <keyword>sepsis</keyword>
  <keyword>St02</keyword>
  <keyword>Near Infrared Spectroscopy</keyword>
  <keyword>NIRS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Shock, Septic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
